Compare iShares MSCI Canada (TSX) (EWC) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.22B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWC | GMED | |
|---|---|---|
Market Cap | $7.22B | $10.25B |
Volume | 1,285,678 | 1,059,528 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $96.82 |
52-Week Low | $49.72 | $58.33 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.91, up 0.77% today, with a bullish technical signal from moving averages but neutral oscillators. The stock faces support at $59 and resistance at $60. Recent news highlights Canada's trade tensions with the U.S. and potential EU associate membership, impacting market sentiment.
Outlook is clouded by trade policy uncertainty, though diversification efforts with India and Europe offer growth avenues. Key risks include U.S. tariff escalations and economic volatility. Analyst sentiment is mixed, balancing geopolitical headwinds against strategic partnerships.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
